Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 17;20(2):384.
doi: 10.3390/ijms20020384.

Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases

Young Mi Whang  1 , Seung Pil Jung  2 , Meyoung-Kon Kim  3 , In Ho Chang  4 , Serk In Park  5   6
Affiliations
Review

Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases

Young Mi Whang et al. Int J Mol Sci. .

Abstract

Bone metastasis is the terminal stage disease of prostate, breast, renal, and lung cancers, and currently no therapeutic approach effectively cures or prevents its progression to bone metastasis. One of the hurdles to the development of new drugs for bone metastasis is the complexity and heterogeneity of the cellular components in the metastatic bone microenvironment. For example, bone cells, including osteoblasts, osteoclasts, and osteocytes, and the bone marrow cells of diverse hematopoietic lineages interact with each other via numerous cytokines and receptors. c-Met tyrosine kinase receptor and its sole ligand hepatocyte growth factor (HGF) are enriched in the bone microenvironment, and their expression correlates with the progression of bone metastasis. However, no drugs or antibodies targeting the c-Met/HGF signaling axis are currently available in bone metastatic patients. This significant discrepancy should be overcome by further investigation of the roles and regulation of c-Met and HGF in the metastatic bone microenvironment. This review paper summarizes the key findings of c-Met and HGF in the development of novel therapeutic approaches for bone metastasis.

Keywords: bone; bone marrow; c-Met and hepatocyte growth factor; metastasis; microenvironment; osteoblasts; osteoclasts.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Park S.I., Soki F.N., McCauley L.K. Roles of bone marrow cells in skeletal metastases: No longer bystanders. Cancer Microenviron. 2011;4:237–246. doi: 10.1007/s12307-011-0081-8. - DOI - PMC - PubMed
    1. Buenrostro D., Park S.I., Sterling J.A. Dissecting the role of bone marrow stromal cells on bone metastases. Biomed. Res. Int. 2014;2014:875305. doi: 10.1155/2014/875305. - DOI - PMC - PubMed
    1. Croucher P.I., McDonald M.M., Martin T.J. Bone metastasis: The importance of the neighbourhood. Nat. Rev. Cancer. 2016;16:373. doi: 10.1038/nrc.2016.44. - DOI - PubMed
    1. Sousa S., Clézardin P. Bone-Targeted Therapies in Cancer-Induced Bone Disease. Calcif. Tissue Int. 2018;102:227–250. doi: 10.1007/s00223-017-0353-5. - DOI - PubMed
    1. Park S.H., Keller E.T., Shiozawa Y. Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif. Tissue Int. 2018;102:152–162. doi: 10.1007/s00223-017-0350-8. - DOI - PMC - PubMed

MeSH terms